ORANGEBURG, N.Y., April 20, 2009 (GLOBE NEWSWIRE) -- IMPULSE Dynamics,
manufacturer of the OPTIMIZER System for patients with heart failure, announced
today that it has recently closed a new round of financing of $40MM USD from
institutional and private investors that will provide the necessary capital for
realizing its strategic plans.
The OPTIMIZER System, which is CE marked, is commercially available in parts of
Europe and Asia and is being investigated in the United States, and delivers
cardiac contractility modulating (CCM) signals that are intended to improve the
strength of heart muscle contraction. IMPULSE Dynamics recently released the
findings of its 428 patient one year study of the OPTIMIZER System conducted in
the U.S. Heart failure is a disease that affects more than 22 million people
around the world, many of which have no treatment options.
"This new financing, coupled with the recently available results of our U.S.
study will provide IMPULSE Dynamics the opportunity to enhance commercial
activities outside of the U.S. and form the foundation for obtaining additional
data to gain approval of the OPTIMIZER System by the U.S. Food and Drug
Administration," stated Dr. Yuval Mika, chief operating officer, IMPULSE
Dynamics.
About IMPULSE Dynamics
IMPULSE Dynamics, with offices in U.S., Switzerland and Israel, is a pioneering
medical device company focused on the development and commercialization of the
OPTIMIZER System, an implantable device for the treatment of medically
refractory heart failure. Additional information can be found at
www.impulse-dynamics.com.
Forward-Looking Statements
This press release contains forward-looking statements about IMPULSE Dynamics,
including projections about its business and the congestive heart failure
market. These forward-looking statements are not guarantees of future
performance and actual results could differ significantly.
CONTACT: IMPULSE Dynamics
Yuval Mika, Chief Operating Officer
(845) 228-3561
yuvalm@impulse-dynamics.com
IMPULSE Dynamics Announces Closing On New Financing Allowing Acceleration of European Commercial Efforts and Clinical Investigation in the U.S.
| Source: Impulse Dynamics Inc.